MedTrace Logo

Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)

NCT01911637 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-12-31

No results posted yet for this study

Summary

VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable single dose of VBY-036 in healthy volunteers. Volunteers are randomly selected to receive one dose of either a placebo or VBY-036 (10, 30, 100, 300, 600 or 900 mg).

Conditions

  • Healthy

Interventions

DRUG

VBY-036

Study drug VBY-036

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Virobay Inc.

    lead INDUSTRY

Principal Investigators

  • David B. Karpf, MD · Virobay Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01911637 on ClinicalTrials.gov